BillionToOne, Inc.

Money is earned per completed test rather than through subscriptions or long contracts, recognized at the point a result is delivered to the ordering physician, with the amount actually collected varying because each test is billed to a mix of private insurers, government health programs such as Medicare and Medicaid, or the patient directly. Nearly all of this revenue comes from prenatal testing, with a much smaller share from oncology testing and a minor share from clinical-trial support work.

It scales primarily by expanding physical laboratory capacity rather than by simple replication: its own account describes building a large new laboratory facility in Texas specifically to substantially expand how much testing it can process beyond its current operations, consistent with a business whose growth in test volume depends on how much physical processing capacity it has, not on demand alone. CompanyGraph's reading of its financial structure describes a configuration carrying more cash than debt, with liquidity elevated relative to industry peers and a meaningful ongoing depreciation charge relative to its cash flow, consistent with a capital-intensive operation that funds capacity growth substantially from its own resources rather than through heavy borrowing.

Its own filings describe dependence on outside suppliers for raw materials, components and specialized biotechnology equipment and services, including inputs tied to foreign entities that fall under emerging biosecurity-related trade restrictions. It also depends on physicians to order its tests, since patients access testing through a physician rather than directly, and on a mix of private insurers, government health programs and individual patients to actually collect payment once a test is complete.

Its own disclosures state that no single customer accounts for a meaningful share of its revenue or receivables in any recent year, so the parties that rely on it are broadly spread rather than concentrated in a few large accounts. The parties closest to that dependence are the ordering physicians and the clinics they work within, who depend on it to return results used in clinical decisions, and its own account of customer retention is measured at the level of these clinic relationships rather than a small number of named accounts.

The company itself states that what sets it apart is a proprietary single-molecule counting technology platform, its specific product lineup, and its ability to grow quickly and efficiently, but this is the company's own characterization of itself rather than something CompanyGraph has independently verified against rival firms. Structurally, CompanyGraph places it among a large number of other companies that run the same underlying kind of production system, a common configuration rather than a rare one, which says nothing on its own about whether this company's specific technology or products could be replicated.

Its own account reports that net retention across most quarterly clinic groups has stayed above the level needed just to replace departing accounts and providers, describing the resulting churn as low without disclosing a specific rate or the mechanism behind it. Long-term contracts do not appear to explain this: the value of business it has committed under agreements running beyond one year is small next to its overall revenue, so whatever keeps these relationships in place is not primarily contractual lock-in.

The general comparison frame CompanyGraph checks production businesses like this one against is a physical processing ceiling: a fixed set of equipment and lab space that can only convert a limited number of samples into results in a given stretch of time, expandable only by adding more physical capacity. This company's own account is consistent with that frame: it describes building a large new laboratory facility specifically to expand how much testing it can process well beyond what its existing operations can handle, which on its own account signals that current processing capacity is a limit it is actively building around.

Its own filings name trade-policy exposure as a specific risk: tariffs, sanctions or trade barriers could raise the cost of its raw materials, components and finished goods, or disrupt its suppliers and distribution channels, and it separately names emerging biosecurity-related restrictions on biotechnology equipment and services sourced from certain foreign entities. It also discloses that it receives government requests and subpoenas concerning Medicaid patient billing records, pointing to reimbursement and compliance scrutiny tied to government health programs as a live area of exposure, even though it states that no formal legal proceeding is currently pending.

Its own filings name a stack of regulators and accreditors that govern how it can operate, including national oversight of diagnostic products and of laboratory testing, a laboratory accreditation body, and separate laboratory licenses it holds in multiple individual states, alongside named tariff, sanctions and trade-barrier risk to its raw materials, components, finished goods and biotechnology equipment sourced from certain foreign entities. It also reports responding to government document requests and subpoenas concerning Medicaid patient billing records, while stating that no formal legal proceeding is currently pending against it.